PRE-CONGRESS WORKSHOPS
APRIL 1, 2024
WALTER E CONVENTION CENTER WASHINGTON DC
World Vaccine Congress Washington 2024's highly anticipate pre-congress workshops are back!
Designed for in-depth discussions and insights into vaccine progress, our workshops on April 1, 2024 cover various domains, including new vaccine technology, biodefense, antimicrobial resistance, global health, RNA, and vaccine delivery. Join our pre-congress workshops on April 01, 2024.
Reserve your seat today with our discount ticket package ,which grants you access to: Workshops (April 1, 2024) (a full-day workshop or the flexibility to choose one morning workshop and one afternoon workshop) , Conference Sessions (April 2-4, 2024) and Exhibition (April 2-4, 2024)
How are international governments incentivizing R&D innovation in industry and what multi-stakeholder initiatives are paving the way for a better prepared future?
- 10:00 am: Workshop leader Opening remarks
- 10:10 am: Lightening talks on technology
- 11:00 am: Government-private partnerships to foster innovation
- Networking break
- 02:00 pm: International collaborations: A multistakeholder effort for “regulatory preparedness”: A global framework designed to enhance regulatory preparedness and speed the access to vaccines during public health emergencies
- 03:00 pm: Panel - Working together to achieve a 100 days mission facility to detect threats at source and control threats
- 04:00 pm: Panel - Biosecurity considerations with pandemic preparedness and the 100 day mission
- Matt Hepburn, CMO, JPEO-CBRND
- Andrew Kilianski, Program Manager, ARPA-H
- Dr Deborah Williamson, UKHSA
- Dr Melanie Saville, Executive Director of Vaccine Research & Development, CEPI
- Rajinder Suri, CEO, DVCMN
- Wolfgang Philipp, Director-General, HERA, European Commission
A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?
Agenda:
- 10:00 am: Chair opening remarks
- 10:10 am: Vaccines for AMR report update
- 10:30 am: Accelerating the Development of Novel Tools against AMR
- 11:00 am: A novel antibiotic against multi-drug resistant gonorrhea
- 11:20 am: The application of phages to treat bacterial infections
- 11:40 am: Diagnostic tools to improve testing and surveillance
- 12:00 pm: What is our global AMR strategy: ESKAPE and Priority Pathogens
- Networking break
- 2.00 pm: Developing vaccines for bacterial pathogens: industry perspective
- 3.00 pm: Serotype Independent Pneumococcal Vaccine
- 3:45 pm: Update on C. diff vaccine development
- 4:00 pm: Defining the value of vaccines against AMR
- Dr Richard Alm , Chief Scientist, CARB-X
- Tim Cooke, CEO, Omniose
- Bret Sellman, Executive Director, Vaccine and Immune Therapies and Head of Bacteriology and Vaccines Discovery, Astrazeneca
- Dr Francesca Micoli, Director GVGH Innovation Academy and Senior Project Leader, GSK Vaccine Institute for Global Health
- Dr Tim Hirst, CEO, GPN Vaccines
- Dr Jomana Musmar, Executive Director, PACCARB
- Leonard Friedland, Vice President of Scientific Affairs and Public Health Vaccines, GSK
More to be confirmed...
Cutting-edge technologies shaping the future of vaccine development.
Agenda:
- 10:10am: Multiplexed VaxArray Immunoassay Workflow for Simultaneous Characterization of 24 Pneumococcal Vaccine Antigens
- 10:45 am: Bacterial Vaccine Polypeptides: Can We Eliminate Otitis Media and Antibiotic Use in Infants?
- 11:00 am: OMV-adjuvanted Spike/RBD vaccine efficacy in mice
- 11:15 am: Co-adjuvants
- 11:45 am: MF59 Adjuvant Mimic: yeast derived squalene and alternative sources
- 12:00 pm: Novel Adjuvants, Delivery Systems, & Approaches For Paediatric Vaccines
Workshop Speakers:
- Dr Lisa Morici, Associate Professor, Tulane University School of Medicine
- Dr Wolfgang Leitner, Chief, Innate Immunity Section, NIH
- Jay Evans, Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine, University of Montana
- Chase Kempinski, Chief Executive Officer , Enepret
More to be confirmed…
There are significant gaps in mAbs access and availability in LMICs. Viable models, commercial incentives and pathways to afford access are currently not in place. Find out how Public-Private collaboration will be needed to bridge this gap.
Agenda:
- 10.00 am: Chair opening remarks
- 10:20 am: Challenges and opportunities: What are the barriers and unique considerations for mAbs accessibility/availability in LMICs? What advancements have recently been achieved and how can they be further leveraged for infectious disease mAbs?
- 11:20 am: Industry perspectives on a path towards access and the role of global health stakeholders
Workshop speakers:
- Carmen Pérez Casas, Strategy Senior Lead / PPPR Head, Unitaid
- Shelly Malhotra, Executive Director, Global Access, IAVI
- Esteban Burrone, Head of Policy, Strategy and Market Access, Medicines Patent Pool
- Pete Gardiner, Research Lead, Antibodies & Immunity, Wellcome Trust
More to be confirmed...
How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?
Agenda:
- 10:00 am: Chair opening remarks
- 10:10 am: Next generation RNA vaccines
- 12:00 pm: Beyond prophylactic vaccines: the future of RNA therapeutics
- 2.00 pm: Beyond Efficacy: Innovating vaccine development and implementation for impact
- Dr Micheal Breen, Scientist, Tiba Biotech
- Dr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC
- Dr Angus Thomson, Principal, Irimi Company
- Hamilton Bennett, Sr. Director Vaccine Access, and Partnerships, Moderna
- Jason Zhang, CEO and Co-Founder, ZipCode Bio
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
Agenda:
- 2:00 pm: Workshop Leader Opening Remarks
- 2:10 pm: Microneedle patches: Mumps
- 2:30 pm: Redefining Access: Plastic Innovation for Prefilled injectables for Safe and Efficient Vaccine Delivery
- 3:00 pm: RNA & MAP - Combining Breakthrough Innovations
- 3:30 pm: Showcase MAPs featuring ceramic nano pores that boost vaccine delivery
- 3:45 pm: Needle-free systems for intra-dermal, -muscular and subcutaneous injections
- 4:15 pm: Enhancing Vaccine Performance with a High-Density Microarray Patch
Workshop Speakers:
- Stephen Crooke, Vaccine Immunology Lead, Viral Vaccine Preventable Diseases, Center for Disease Control and Prevention
- Dr Markus Winterberg, Head of Analytical Development, Microbiology, and Quality Control, LTS Lohmann
- Dr Dennis Christensen, Global Head of R&D, Adjuvant Systems, CRODA
- Dr Erin Spiegel, VP, Clinical and Regulatory Affairs, PharmaJet
More to confirmed…
Identifying innovative and collaborative solutions throughout the development pathway to advance NTD vaccine candidates beyond historical roadblocks.
Agenda:
- 2:00 pm: Workshop Leader Opening Remarks
- 2:20 pm: Optimizing pre-clinical frameworks to maximize successful transition of NTD vaccines into the critical path
- 3:20 pm: Navigating the Critical Path: Advancing NTD Vaccines Beyond Phase II
- 4:15 pm: Transnational & Regional Approaches to Pandemic Preparedness
Workshop Speakers:
- Dr Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute Director, GSK
- Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital for Vaccine Development, Baylor College of Medicine
- Dr Phillip Felgner, Director, UCI Vaccine Research & Development Center & Protein Microarray Laboratory and Training Facility, University of California Irvine
- Dr Orin Levine, Non-Resident Fellow, Center for Global Development
- Dr David Diemert, Professor & Clinical Director, GW Vaccine Research Unit, The George Washington University
- Jerome Kim, Director General, IVI
Vaccine efficacy is only one determinant of vaccine impact. This workshop will explore innovations throughout the development of a novel vaccine which may ensure better access and equity.
The themes of this workshop will challenge our thinking, our dogmas and perhaps reveal new horizons. It honours
Dr Mike Watson
, a true vaccinologist and original thinker.
Agenda:
Workshop Speakers:
- Dr Angus Thomson, Principal, Irimi Company
- Hamilton Bennett, Sr. Director Vaccine and Access Partnerships, Moderna
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events